Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06045325 · ClinicalTrials.gov registry record
Assessment of Measurement Variability Across Automated Biometry Devices
A clinical trial, sponsored by Berkeley Eye Center.
- Completed
- Registry status
- 204
- Enrollment target
NCT06045325: Completed study, sponsored by Berkeley Eye Center.
NCT06045325 is a clinical trial that has completed, run by Berkeley Eye Center. The registered enrollment target is 204 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06045325 has completed, sponsored by Berkeley Eye Center.
- COMPLETED
- Registry status
- 204 participants
- Enrollment target
Study Summary
This is a non-interventional prospective, comparative study of white-to-white, corneal thickness, and anterior chamber depth measurements as taken on the Orbscan II compared to the IOL Master 700 (Zeiss), IOL Master 500 (Zeiss), Atlas 9000 (Zeiss), Lenstar 900 (Haag-Streit), Argos (Alcon), iTrace (Tracey), Pentacam (Oculus), and manual calipers.
Primary Outcome
The determination of the degree of correlation of white-to-white measurements between various biometric devices and the Orbscan II.
Interventions
- DIAGNOSTIC_TEST Orbscan II
- DIAGNOSTIC_TEST IOL Master 700
- DIAGNOSTIC_TEST IOL Master 500
- DIAGNOSTIC_TEST Atlas 9000
- DIAGNOSTIC_TEST Lenstar 900
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2024-02-16 |
What the finished NCT06045325 record still lists
NCT06045325 is an observational study that tracks outcomes without assigning an intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which Orbscan II is the first listed.
NCT06045325 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06045325 about?
NCT06045325 is a clinical study titled "Assessment of Measurement Variability Across Automated Biometry Devices". This is a non-interventional prospective, comparative study of white-to-white, corneal thickness, and anterior chamber depth measurements as taken on the Orbscan II compared to the IOL Master 700 (Zeiss), IOL Master 500 (Zeiss), Atlas 9000 (Zeiss), Lenstar 900 (Haag-Streit), Argos (Alcon), iTrace (T...
What is the current status of trial NCT06045325?
This trial is currently completed. The enrollment target is 204 participants. The study started on 2023-07-25. Estimated completion is 2024-02-16.
What interventions are being tested in trial NCT06045325?
The interventions under investigation include: Orbscan II (DIAGNOSTIC_TEST), IOL Master 700 (DIAGNOSTIC_TEST), IOL Master 500 (DIAGNOSTIC_TEST), Atlas 9000 (DIAGNOSTIC_TEST), Lenstar 900 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06045325?
This trial is sponsored by Berkeley Eye Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI